Immunosuppressive and Anti-inflammatory Properties of Interleukin 10

References

• Mosmann T R, Coffman R T. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73
   PubMed Web of Science ®Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227–57
   PubMed Web of Science ®Google Scholar
• Fiorentino D F, Bond M W, Mosmann T R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081–5
   PubMed Web of Science ®Google Scholar
• Yssel H, de Waal Malefyt R, Roncarolo M G, Abrams J S, Lahesmaa R, de Vries J E. IL-10 produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 1992; 149: 2378–84
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduced antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class major histocompatibility complex expression. J Exp Med 1991; 174: 915–24
   PubMed Web of Science ®Google Scholar
• O'Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 1990; 2: 821–32
   PubMed Web of Science ®Google Scholar
• Enk A H, Katz S I. Identification and induction of keratinocytes-derived IL-10. J Immunol 1992; 149: 92–5
   PubMed Web of Science ®Google Scholar
• Burdin N, Peronne C, Banchereau J, Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med 1993; 177: 295–304
   PubMed Web of Science ®Google Scholar
• Benjamin D, Knobloch T J, Dayton M A. Human B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Stood 1992; 80: 1289–98
   Google Scholar
• Moore K W, O'Garra A, de Waal Malefyt R, Vieira R, Mosmann T R. Interleukin 10. Annu Rev Immunol 1993; 11: 165–90
   PubMed Web of Science ®Google Scholar
• Vieira P, de Waal Malefyt R, Dang M N, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991; 88: 1172–6
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Yssel H, Roncarolo M G, Spits H, de Vries J E. Interleukin-10. Curr Opin Immunol 1992; 4: 314–20
   PubMed Web of Science ®Google Scholar
• Ho A SY, Moore K W. Interleukin-10 and its receptor. Ther Immunol 1994; 1: 173–85
   PubMedGoogle Scholar
• June C H, Bluestone J A, Nadler L M, Thompson C B. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321–31
   PubMedGoogle Scholar
• Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76–9
   PubMed Web of Science ®Google Scholar
• Spits H, van Schooten W, Keizer H, et al. Alloantigen recognition is preceded by nonspecific adhesion of cytotoxic T cells and target cells. Science 1986; 232: 403–5
   PubMed Web of Science ®Google Scholar
• Matsui K, Boniface J J, Reay P A, Schild H, Fazekas de St Groth B, Davis M M. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991; 254: 1788–91
   PubMed Web of Science ®Google Scholar
• Bejarano M T, de Waal Malefyt R, Abrams J S, et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary lymphocyte cultures. Int Immunol 1992; 4: 1389–97
   PubMed Web of Science ®Google Scholar
• Peguet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J, Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol 1994; 24: 884–91
   PubMed Web of Science ®Google Scholar
• Caux C, Massacrier C, Vanbervllet B, Barthelemy C, Liu Y J, Banchereau J. Interleukin-10 inhibits T-cell alloreaction induced by human dendritic cells. Int Immunol 1994; 6: 1177–85
   PubMed Web of Science ®Google Scholar
• Ding L, Llnsley P S, Huang L Y, Germain R N, Shevach E M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224–34
   PubMed Web of Science ®Google Scholar
• Willems F, Marchant A, Deiville J P, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007–9
   PubMed Web of Science ®Google Scholar
• Kubin M, Kamoun M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180: 211–22
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Figdor C, de Vries J E. Regulation of human monocyte functions by interleukin-10. Interleukin 10, J E de Vries, R de Waal Malefyt. R.G. Landes Company, Austin, TX 1995; 37–52
   Google Scholar
• de Waal Malefyt R, Yssel H, de Vries J E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. J Immunol 1993; 150: 4754–65
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor C G, de Vries J E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–20
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Figdor C, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes: Comparison to IL-4 and modulation by IFN-y or IL-10. J Immunol 1993; 151: 6370–81
   PubMed Web of Science ®Google Scholar
• Baggiolini M, Dewald B, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines — CXC and CC chemokines. Adv Immunol 1994; 55: 97–179
   PubMed Web of Science ®Google Scholar
• Cassatella M A, Meda L, Bonora-Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993; 178: 2207–11
   PubMed Web of Science ®Google Scholar
• Kasama T, Stricter R M, Lukacs N W, Burdick M D, Kunkel S L. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994; 152: 3559–69
   PubMed Web of Science ®Google Scholar
• Wang P, Wu P, Anthes J C, Siegel M I, Egan R W, Billah M M. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 1994; 83: 2678–83
   PubMed Web of Science ®Google Scholar
• Takanaski S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokines production by human peripheral blood eosinophils. J Exp Med 1994; 180: 711–5
   PubMed Web of Science ®Google Scholar
• Jenkins J K, Malyak M, Arend W P. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994; 13: 47–54
   PubMedGoogle Scholar
• Cassatella M A, Meda L, Gasperinl S, Calzetti F, Bonora S. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179: 1695–9
   PubMed Web of Science ®Google Scholar
• Chomarat P, Rissoan M-C, Banchereau J, Miossec P. Interferon y inhibits interleukin 10 production by monocytes. J Exp Med 1993; 177: 523–7
   PubMed Web of Science ®Google Scholar
• Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205–8
   PubMed Web of Science ®Google Scholar
• Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumour necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547–50
   PubMed Web of Science ®Google Scholar
• Bean A G, Freiberg R A, Andrade S, Menon S, Zlotnik A. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993; 61: 4937–9
   PubMed Web of Science ®Google Scholar
• Drake C G, Kotzin B L. Superantigens: biology, immunology and potential role in disease. J Clin Immunol 1992; 12: 149–62
   PubMed Web of Science ®Google Scholar
• Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer P H, Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumour necrosis factor. J Exp Med 1992; 175: 91–8
   PubMed Web of Science ®Google Scholar
• Fiorentlno D F, Ziotnik A, Vieira P, et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444–51
   PubMed Web of Science ®Google Scholar
• Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–74
   PubMed Web of Science ®Google Scholar
• Powrie F, Leach M W, Mauze S, Caddle L B, Coffman R L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5: 1461–71
   PubMed Web of Science ®Google Scholar
• Powrie F, Leach M W, Mauze S, Menon S, Caddie L B, Coffman R L. Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with cd45rbhi CD4+ T cells. Immunity 1994; 1: 553–62
   PubMed Web of Science ®Google Scholar
• Chernoff Granowitz E V, Shapiro L, . A phase I study of interleukin-10 in healthy humans: safety and effects on cytokine production. Interleukin 10, J E de Vries, R de Waal Malefyt, et al. R.G. Landes Company, Austin, TX 1995; 148–58
   Google Scholar
• Rousset F, Garcia E, Defrance T, et al. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890–3
   PubMed Web of Science ®Google Scholar
• Pennline K J, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71: 169–75
   PubMedGoogle Scholar
• Bacchetta R, Bigler M, Touraine J-L, et al. High levels of IL-10 production in vivo are associated with tolerance in a SCID patient transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493–502
   PubMed Web of Science ®Google Scholar